Results 221 to 230 of about 804,492 (282)

Workshop on manpower development and training in toxicology and chemical safety. Luxembourg, 28 November - 2 December 1983. Industrial health and safety. EUR 9619 EN [PDF]

, 1984
Berlin, A., Smith, E., Tarkowski, S.
core  

Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.
Roxane Dilcher, Charles B. Malpas, Stuart J. McDonald, William T. O’Brien, Craig Despott, Kelly L. Bertram, Matthew P. Pase, Lukas Frontzkowski, Meng Law, Terence J. O’Brien, Lucy Vivash   +10 more
wiley   +1 more source

Short communication: Dynamic chemical labelling allows the measurement of the paracetamol toxicity biomarker microRNA-122 in hospital clinical laboratories. [PDF]

Br J Clin Pharmacol
Alzeer S, Marin-Romero A, López-Longarela B, Guardia-Monteagudo JJ, Lopez-Delgado FJ, Pernagallo S, Diaz-Mochon JJ, Tabraue-Chavez M, Scullion K, Dear JW.   +9 more
europepmc   +1 more source

Complementarity of Long‐Reads and Optical Mapping in Parkinson's Disease for Structural Variants

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Long‐read sequencing and optical genome mapping technologies have the ability to detect large and complex structural variants. This has led to the discovery of novel pathogenic variants in neurodegenerative movement disorders. Thus, we aimed to systematically compare the SV detection capabilities of OGM and ONT in Parkinson's disease.
André Fienemann, Theresa Lüth, Susen Schaake, Carolin Gabbert, Marius Möller, Hauke Busch, Katja Lohmann, Jonas A. Gustafson, Danny E. Miller, Kensuke Daida, Manabu Funayama, Nobutaka Hattori, Samia Ben Sassi, Faycel Hentati, Matthew J. Farrer, Kristian K. Ullrich, Christine Klein, Joanne Trinh   +17 more
wiley   +1 more source

Two decades of bacteraemia in Norway: an ecological study of incidence and shifts in microbial epidemiology, 2005-2024. [PDF]

Sci Rep
Danielsen AS, Johansen A, Sare M, Lim C, Bjørnholt JV, Furberg AS, Simonsen GS.   +6 more
europepmc   +1 more source

Reduction in Renal Relapse and Preservation of Long‐Term Kidney Function After Lupus Low Disease Activity in Patients With Lupus Nephritis

Arthritis Care &Research, EarlyView.
Objective Lupus low disease activity state (LLDAS) is a validated treatment target in systemic lupus erythematosus (SLE), but limited studies have explored the role of LLDAS in lupus nephritis (LN). This study aims to investigate the frequency and predictors of LLDAS attainment and its benefit on LN relapse and renal function preservation in patients ...
Chak Kwan Cheung, Desmond Y. H. Yap, Ka Lai Lee, Philip H. Li, Iris Y. K. Tang, Chak Sing Lau, Shirley C. W. Chan   +6 more
wiley   +1 more source

Multicenter Evaluation of Different Anti-Xa Assays and Diluted Russell's Viper Venom Time in Ex Vivo Plasma Samples from Patients Treated with Rivaroxaban or Apixaban. [PDF]

J Clin Med
Božič Mijovski M, Mavri A, Antovic JP, Malmström RE, Coen Herak D.   +4 more
europepmc   +1 more source

A Scoping Review on Artificial Intelligence–Supported Interventions for Nonpharmacologic Management of Chronic Rheumatic Diseases

Arthritis Care &Research, EarlyView.
This review summarizes artificial intelligence (AI)‐supported nonpharmacological interventions for adults with chronic rheumatic diseases, detailing their components, purpose, and current evidence base. We searched Embase, PubMed, Cochrane, and Scopus databases for studies describing AI‐supported interventions for adults with chronic rheumatic diseases.
Nirali Shah, Alexis Castellanos, Yen Chen, John Piette, Amy Bucher, Susan Murphy   +5 more
wiley   +1 more source

Hydroxychloroquine Associated With Lower Glomerular Filtration Rate Decline in Lupus Nephritis

Arthritis Care &Research, EarlyView.
Objective Hydroxychloroquine (HCQ) protects kidney function in lupus nephritis (LN) by preventing flares, yet some cohort studies show no significant benefit in kidney function with HCQ. Clarifying these conflicting findings by showing early and long‐term benefits of HCQ on kidney function preservation is critical.
Shivani Garg, Brad Rovin, Brad C. Astor, Tripti Singh, Fauzia Hollnagel, Megan Kuik, Lexie Kolton, Callie Saric, S. Sam Lim, Christie M. Bartels   +9 more
wiley   +1 more source